Wild-type p53 has been reported to repress the Warburg effect in cancer cells through transactivating target genes that are required for oxidative phosphorylation, such as SCO2 (Matoba et al., 2006), as well as genes such as TIGAR and Parkin to negatively regulate glycolysis (Bensaad et al., 2006; Zhang et al., 2011; Liu et al., 2017b). The gene discussed is TP53; the disease is cancer.